Study of Cilostazol and Probucol to Assess Their Effects on Atherosclerosis Related Biomarker

NCT00823849 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus
Arteriosclerosis Obliterans

Interventions

DRUG: Cilostazol
DRUG: Probucol
DRUG: Cilostazol+Probucol
OTHER: Control Group

Sponsor

Otsuka Beijing Research Institute